search
Back to results

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

Primary Purpose

Hepatitis C

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
bavituximab
Sponsored by
Peregrine Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatitis C focused on measuring HCV, monoclonal antibody, phase 1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: At least 18 years of age Chronic Hepatitis C infection based on history and detectable serum HCV RNA including treatment naïve subjects as well as subjects who are partial responders and/or relapsers to prior therapy(ies) All genotypes of HCV acceptable Complete Blood Counts within normal limits Normal renal function (serum creatinine within normal limits) Normal coagulation profile (PT/INR and aPTT within normal limits) Patients of reproductive potential must agree to use an approved form of barrier contraception. Female patients must have a negative serum pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal) Exclusion Criteria: Prior exposure to any chimeric antibody Any other cause of liver disease other than chronic hepatitis C, such as autoimmune or alcoholic liver disease. Decompensated clinical liver disease, including a history of prolonged clotting times, hypoalbuminemia, encephalopathy, treatment for elevated ammonia levels, or ascites Any evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or gastrointestinal bleeding Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease or Hemophilia) Any history of thromboembolic events [e.g., deep vein thrombosis (DVT) or pulmonary thromboembolism (PE)] including central venous catheter-related thrombosis within the past 12 months Concurrent therapy with oral or parenteral anticoagulants Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement, anti-estrogen) Antiviral therapy within 4 weeks of day 0 Investigational therapy within 4 weeks of day 0 Major surgery within 4 weeks of day 0 Pregnant or nursing women Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease) Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin A history of any condition requiring treatment (past or current) with coumarin-type agents Cardiac arrhythmia requiring medical therapy Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture) Requirement for chronic daily treatment with NSAIDs, antiplatelet drugs (e.g., phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), or steroids Cancer, autoimmune disease or any disease or concurrent therapy known to cause significant alteration in immunologic function Known chronic infection with HIV or HBV

Sites / Locations

  • University Hepatitis Center at Bach & Godofsky MD PA
  • Alamo Medical Research

Outcomes

Primary Outcome Measures

adverse events
laboratory evaluations
human anti-chimeric antibody
pharmacokinetic analysis
viral kinetic analysis
cytokine analysis

Secondary Outcome Measures

Full Information

First Posted
June 21, 2006
Last Updated
April 28, 2008
Sponsor
Peregrine Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00343525
Brief Title
Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
Official Title
A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients With Chronic Hepatitis C
Study Type
Interventional

2. Study Status

Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Peregrine Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via an arm vein as multiple infusions and to examine how bavituximab behaves in the body and how it effects the amount of hepatitis C virus and immune modulators in individuals with chronic infection.
Detailed Description
Hepatitis C virus (HCV) infection is a world wide public health concern and is the most common chronic bloodborne infection in the United States and the leading indication for liver transplantation. Laboratory and animal studies have demonstrated that bavituximab binds viruses and virally infected cells and prolongs survival in lethally infected animals. This study will examine the safety and tolerability of bavituximab when administered as multiple infusions to patients with chronic HCV infection. Groups of patients will be treated with escalating doses of bavituximab twice weekly for 2 weeks and followed for 12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C
Keywords
HCV, monoclonal antibody, phase 1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
bavituximab
Primary Outcome Measure Information:
Title
adverse events
Title
laboratory evaluations
Title
human anti-chimeric antibody
Title
pharmacokinetic analysis
Title
viral kinetic analysis
Title
cytokine analysis

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years of age Chronic Hepatitis C infection based on history and detectable serum HCV RNA including treatment naïve subjects as well as subjects who are partial responders and/or relapsers to prior therapy(ies) All genotypes of HCV acceptable Complete Blood Counts within normal limits Normal renal function (serum creatinine within normal limits) Normal coagulation profile (PT/INR and aPTT within normal limits) Patients of reproductive potential must agree to use an approved form of barrier contraception. Female patients must have a negative serum pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal) Exclusion Criteria: Prior exposure to any chimeric antibody Any other cause of liver disease other than chronic hepatitis C, such as autoimmune or alcoholic liver disease. Decompensated clinical liver disease, including a history of prolonged clotting times, hypoalbuminemia, encephalopathy, treatment for elevated ammonia levels, or ascites Any evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or gastrointestinal bleeding Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease or Hemophilia) Any history of thromboembolic events [e.g., deep vein thrombosis (DVT) or pulmonary thromboembolism (PE)] including central venous catheter-related thrombosis within the past 12 months Concurrent therapy with oral or parenteral anticoagulants Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement, anti-estrogen) Antiviral therapy within 4 weeks of day 0 Investigational therapy within 4 weeks of day 0 Major surgery within 4 weeks of day 0 Pregnant or nursing women Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease) Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin A history of any condition requiring treatment (past or current) with coumarin-type agents Cardiac arrhythmia requiring medical therapy Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture) Requirement for chronic daily treatment with NSAIDs, antiplatelet drugs (e.g., phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), or steroids Cancer, autoimmune disease or any disease or concurrent therapy known to cause significant alteration in immunologic function Known chronic infection with HIV or HBV
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Lawitz, MD
Organizational Affiliation
Alamo Medical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eliot W Godofsky, MD
Organizational Affiliation
University Hepatitis Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hepatitis Center at Bach & Godofsky MD PA
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34243
Country
United States
Facility Name
Alamo Medical Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

We'll reach out to this number within 24 hrs